TrialClinical endocrinology2026

Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre-Specified Secondary Analysis of the TVFR Trial.

Annabelle M Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.